This research is testing a new drug called **daraxonrasib** against a standard chemotherapy drug, **docetaxel**, for adults with a type of lung cancer called NSCLC (Non-Small Cell Lung Cancer). NSCLC is a type of cancer that affects the lungs and has certain genetic changes called **RAS mutations**. The study will see if daraxonrasib helps patients live longer or slows down the cancer compared to docetaxel.

Participants will be randomly assigned to one of two groups: one group will receive daraxonrasib, and the other will receive docetaxel. This study is open-label, meaning everyone involved knows which treatment the participants are getting.

• The study is global and involves patients previously treated for NSCLC.
• Participants need to be at least 18 years old and able to take pills.
• People with untreated brain cancer, serious health issues, or who are pregnant can't participate.

Choosing to join this study means regular visits to the doctor, but it might help find better treatments for lung cancer in the future.